TY - JOUR
T1 - Experimental and Emerging Free Fatty Acid Receptor Agonists for the Treatment of Type 2 Diabetes
AU - Patti, Angelo Maria
AU - Giglio, Rosaria Vincenza
AU - Papanas, Nikolaos
AU - Serban, Dragos
AU - Stoian, Anca Pantea
AU - Pafili, Kalliopi
AU - Al Rasadi, Khalid
AU - Rajagopalan, Kanya
AU - Rizvi, Ali A
AU - Ciaccio, Marcello
AU - Rizzo, Manfredi
N1 - Publisher Copyright:
© 2022 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2022/1/11
Y1 - 2022/1/11
N2 - The current management of Type 2 Diabetes Mellitus (T2DM) includes incretin-based treatments able to enhance insulin secretion and peripheral insulin sensitivity as well as improve body mass, inflammation, plasma lipids, blood pressure, and cardiovascular outcomes. Dietary Free Fatty Acids (FFA) regulate metabolic and anti-inflammatory processes through their action on incretins. Selective synthetic ligands for FFA1-4 receptors have been developed as potential treatments for T2DM. To comprehensively review the available evidence for the potential role of FFA receptor agonists in the treatment of T2DM, we performed an electronic database search assessing the association between FFAs, T2DM, inflammation, and incretins. Evidence indicates that FFA1-4 agonism increases insulin sensitivity, induces body mass loss, reduces inflammation, and has beneficial metabolic effects. There is a strong inter-relationship between FFAs and incretins. FFA receptor agonism represents a potential target for the treatment of T2DM and may provide an avenue for the management of cardiometabolic risk in susceptible individuals. Further research promises to shed more light on this emerging topic.
AB - The current management of Type 2 Diabetes Mellitus (T2DM) includes incretin-based treatments able to enhance insulin secretion and peripheral insulin sensitivity as well as improve body mass, inflammation, plasma lipids, blood pressure, and cardiovascular outcomes. Dietary Free Fatty Acids (FFA) regulate metabolic and anti-inflammatory processes through their action on incretins. Selective synthetic ligands for FFA1-4 receptors have been developed as potential treatments for T2DM. To comprehensively review the available evidence for the potential role of FFA receptor agonists in the treatment of T2DM, we performed an electronic database search assessing the association between FFAs, T2DM, inflammation, and incretins. Evidence indicates that FFA1-4 agonism increases insulin sensitivity, induces body mass loss, reduces inflammation, and has beneficial metabolic effects. There is a strong inter-relationship between FFAs and incretins. FFA receptor agonism represents a potential target for the treatment of T2DM and may provide an avenue for the management of cardiometabolic risk in susceptible individuals. Further research promises to shed more light on this emerging topic.
KW - Diabetes Mellitus, Type 2/drug therapy
KW - Fatty Acids, Nonesterified
KW - Humans
KW - Insulin Resistance
KW - Incretins
KW - Type 2 diabetes
KW - GLP-1
KW - Cardiovascular risk
KW - Metabolism
KW - Free fatty acids
UR - http://www.scopus.com/inward/record.url?scp=85123090450&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85123090450&partnerID=8YFLogxK
UR - https://www.mendeley.com/catalogue/92d0cf0a-3c66-3706-bf64-b7a1eeabb81b/
U2 - 10.3390/medicina58010109
DO - 10.3390/medicina58010109
M3 - Review article
C2 - 35056417
SN - 1010-660X
VL - 58
JO - Medicina (Lithuania)
JF - Medicina (Lithuania)
IS - 1
M1 - 109
ER -
